
Contact
Thomas P. Frye, D.O.
View Contact & SchedulingLocations
158 Sawgrass Drive, 2nd Floor, Suite 230
Rochester, NY 14620
About Me
Dr. Frye was the valedictorian of his class where he graduated with a Doctor of Osteopathy degree from Midwestern University, Chicago College of Osteopathic Medicine. He went on to complete his urology residency at Southern Illinois University School of Medicine. Dr. Frye was chosen for the prestigious fellowship training in Urologic Oncology within The National Cancer Institute at the National Institutes of Health (NIH) in Bethesda, Maryland.
Dr. Frye’s research projects focus on optimizing the screening, diagnosis and treatment of men with prostate cancer. During his fellowship, he worked extensively in refining the use of prostate MRIs in men on active surveillance. Dr. Frye's clinical research interest also includes advanced imaging for prostate cancer as well as focal therapy of prostate cancer.
Dr. Frye is involved in multiple specialty societies including the American Urological Association (AUA), Society of Urologic Oncology (SUO), American Society of Clinical Oncology, and Focal Therapy Society.
Certified Specialties
Urology - American Board of Urology
Faculty Appointments
Associate Professor - Department of Urology (SMD)
Credentials
Residency & Fellowship
Fellowship, Urologic Oncology, National Cancer Institute/National Institute of Health. 2014 - 2016
Residency, Urology, Southern Illinois University School Of Medicine. 2010 - 2014
Internship, Urology, Southern Illinois University School Of Medicine. 2009 - 2010
Education
DO | Midwestern University. 2009
Research
Clinical Trials
Lead Researcher: Thomas P Frye
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to othe...
Lead Researcher: Thomas P Frye
The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.
Publications
Journal Articles
Ghazi A, Melnyk R, Hung AJ, Collins J, Ertefaie A, Saba P, Gurung P, Frye T, Rashid H, Wu G, Mottrie A, Costello T, Dasgupta P, Joseph J
BJU international.. 2020 September 16 Epub 09/16/2020.
Gurung PMS, Frye TP, Rashid HH, Joseph JV, Wu G
Urology.. 2020 June 17 Epub 06/17/2020.
Incorporation and validation of clinically relevant performance metrics of simulation (CRPMS) into a novel full-immersion simulation platform for nerve-sparing robot-assisted radical prostatectomy (NS-RARP) utilizing three-dimensional printing and hydrogel casting technology.
Witthaus MW, Farooq S, Melnyk R, Campbell T, Saba P, Mathews E, Ezzat B, Ertefaie A, Frye TP, Wu G, Rashid H, Joseph JV, Ghazi A.
BJU Int. 2020; .
Cribriform pattern and perineural invasion on MR/US fusion biopsy predict failure of selection criteria for prostatic hemigland ablation
Mithal P, Truong M, Quarrier S, Lu D, Hollenberg G, Weinberg E, Miyamoto H, Frye T.
Urol Oncol. 2020; .
Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging
Truong M, Baack Kukreja JE, Rais-Bahrami S, Barashi NS, Wang B, Nuffer Z, Park JH, Lam K, Frye TP, Nix JW, Thomas JV, Feng C, Chapin BF, Davis JW, Hollenberg G, Oto A, Eggener SE, Joseph JV, Weinberg E, Messing EM.
Eur Urol Oncol. 2019; .
Sonographic Diagnosis of Unilateral Synchronous Testicular Tumors
Forrest A, Numbere N, Jean-Gilles J, Frye T, Dogra V.
Am J Sonogr. 2019; .
Joseph JV, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, Yeh SY, Ghazi A, Fultz P, Rubens D, Wu G, Singer E, Schwarz E, Mohile S, Mohler J, Theodorescu D, Lee YF, Okunieff P, McConkey D, Rashid H, Chang C, Fradet Y, Guru K, Kukreja J, Sufrin G, Lotan Y, Bailey H, Noyes K, Schwartz S, Rideout K, Bratslavsky G, Campbell SC, Derweesh I, Abrahamsson PA, Soloway M, Gomella L, Golijanin D, Svatek R, Frye T, Lerner S, Palapattu G, Wilding G, Droller M, Trump D
Bladder cancer.. 2018 October 34 (Suppl 1):S1-S43. Epub 10/03/2018.
A Comprehensive Analysis of Cribriform Morphology on MR/US Fusion Biopsy Correlated with Radical Prostatectomy Specimens.
Truong M, Feng C, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP.
Journal of Urology. 2018; .
Historical and contemporary perspectives on cribriform morphology in prostate cancer.
Truong M, Frye T, Messing E, Miyamoto H.
Nat Rev Urol. 2018; .
Magnetic resonance imaging detection of prostate cancer in men with previous negative prostate biopsy.
Truong M;Frye TP.
Transl Androl Urol. 2017; 6(3): 424-431.
MRI-TRUS Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer
Frye TP, George A, Kilchevsky A, Maruf M, Siddiqui M, Kongnyuy M, Muthigi A, Han H, Parnes H, Merino M, Choyke P, Turkbey B, Wood B, Pinto P.
Journal of Urology. 2017; .
Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric MRI: Correlation with Final Histopathology
Truong M, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP.
Journal of Urology. 2017; .
The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy
Maruf M, Fascelli M, George AK, Siddiqui MM, Kongnyuy M, DiBianco JM, Muthigi A, Valayil S, Sidana A, Frye TP, Kilchevsky A, Choyke PL, Turkbey B, Wood BJ, Pinto PA.
Prostate Cancer Prostatic Dis. 2017; .
Prostate Cancer Diagnosis on repeat MRI-TRUS Fusion Biopsy of Benign Lesions: Recommendations for Repeat Sampling
Chelluri R, Kilchevsky A, George AK, Sidana A, Frye TP, Su D, Fascelli M, Ho R, Abboud SF, Turkbey B, Merino MJ, Choyke PL, Wood BJ, Pinto PA.
J Urol. 2016; : pii: S0022-5347(16)00327-X. doi: 10.1016.
Reproducibility of Multiparametric MRI and Fusion-Guided Prostate Biopsy: Multi-Institutional External Validation by a Propensity Score Matched Cohort
Rastinehad AR, Abboud SF, George AK, Frye T, Ho R, Chelluri R, Fascelli M, Shih J, Villani R, Ben-Levi E, Yaskiv O, Turkbey B, Choyke PL, Merino MJ, Wood BJ, Pinto PA.
J Urol. 2016; pii: S0022-5347(16)00129-4.
Reproducibility of Multiparametric Magnetic Resonance Imaging and Fusion Guided Prostate Biopsy: Multi-Institutional External Validation by a Propensity Score Matched Cohort.
Rastinehad AR, Abboud SF, George AK, Frye T, Ho R, Chelluri R, Fascelli M, Shih J, Villani R, Ben-Levi E, Yaskiv O, Turkbey B, Choyke PL, Merino MJ, Wood BJ, Pinto PA.
Journal of Urology. 2016; .
The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men
Kongnyuy M, Sidana A, George AK, Muthigi A, Iyer A, Fascelli M, Kadakia M, Frye TP, Ho R, Mertan F, Minhaj Siddiqui M, Su D, Merino MJ, Turkbey B, Choyke PL, Wood BJ, Pinto PA.
Urol Oncol. 2016; .
Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification.
18. Muthigi A, Sidana A, George AK, Kongnyuy M, Shakir N, Kadakia M, Maruf M, Frye TP, Mertan F, Su D, Merino MJ, Choyke PL, Turkbey B, Wood BJ, Pinto PA.
Int Urol Nephrol. 2016; .
Preoperative Multiparametric Magnetic Resonance Imaging Predicts Biochemical Recurrence in Prostate Cancer after Radical Prostatectomy
Ho R, Siddiqui MM, George AK, Frye T, Kilchevsky A, Fascelli M, Shakir NA, Chelluri R, Abboud SF, Walton-Diaz A, Sankineni S, Merino MJ, Turkbey B, Choyke PL, Wood BJ, Pinto PA.
PLoS One. 2016; .
Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification
Muthigi A, Sidana A, George AK, Kongnyuy M, Shakir N, Kadakia M, Maruf M, Frye TP, Mertan F, Su D, Merino MJ, Choyke PL, Turkbey B, Wood BJ, Pinto PA.
Int Urol Nephrol. 2016; .
Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers
Watson MJ, George AK, Maruf M, Frye TP, Muthigi A, Kongnyuy M, Valayil SG, Pinto PA.
Future Oncol. 2016; .
Tumor contact with prostate capsule on magnetic resonance imaging: A potential biomarker for staging and prognosis
Kongnyuy M, Sidana A, George AK, Muthigi A, Iyer A, Ho R, Chelluri R, Mertan F, Frye TP, Su D, Merino MJ, Choyke PL, Wood BJ, Pinto PA, Turkbey B.
Urol Oncol. 2016; .
A Case of In-Bore Transperineal MRI-Guided Prostate Biopsy of a Patient with Ileal Pouch-Anal Anastomosis
Kongnyuy M, Frye TP, George AK, et al.
Case Reports in Urology. 2015; .
Combined Biparametric Prostate MRI and Prostate Specific Antigen in the Detection of Prostate Cancer: a Validation Study in a Biopsy Naïve Patient Population
Fascelli M, Rais-Bahrami S, Sankineni S, Brown AM, George AK, Ho R, Frye T, Kilchevsky A, Chelluri R, Abboud S, Siddiqui MM, Merino MJ, Wood BJ, Choyke PL, Pinto PA, Turkbey B.
Urology. 2015; pii: S0090-4295(15)01091-2.
Optimizing Patient Population for MP-MRI and Fusion Biopsy for Prostate Cancer Detection
Frye TP, Pinto PA, George AK.
Curr Urol Rep. 2015; 16(7):50.
The role of MRI in active surveillance for prostate cancer
Fascelli M, George AK, Frye T, Turkbey B, Choyke PL, Pinto PA.
Curr Urol Rep. 2015; 16(6):42.
Impact of County Rurality and Urologist Density on Urologic Cancer Mortality in Illinois
Frye TP, Sadowski DJ, Zahnd WE, Jenkins WD, Dynda DI, Mueller GS, Alanee SR, McVary KT.
J Urol. 2015; 193(5):1608-13.
Conservative management and female gender are associated with increased cancer?specific death in patients with isolated primary urothelial carcinoma in situ.
Alanee S, Bauman J, Dynda D, Frye T, Konety B, Schwartz B.
Eur J Cancer Care (Engl). 2014; .
Robot-Assisted Inguinal Lymphadenectomy for Urethral Carcinoma
Frye TP, Gorbonos A.
J Laparoendoscopic & Advanced Surgical Techniques and Part B: Videoscopy. 2014; .
Ocular Radiation Exposure in Modern Urologic Practice
Taylor ER, Kramer B, Frye TP, Wang S, Schwartz BF, Köhler TSJ.
Urol. 2013; .
Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response
Johnson LE, Frye TP, McNeel DG.
OncoImmunology. 2012; 1;1(9):1546-1556.
Patient Satisfaction of Vacuum Erection Device (VED) Use After Prostate Cancer Treatment: Three and Six Month Outcomes from a VED Registry
Kohler TS, Frye TP, Rewcastle JC, Mulhall JP.
J Sex. Med. 2012; 9:219.
HLA-A2 restricted T-cell epitopes specific for prostatic acid phosphatase
Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG . 2010 Jun;.
Cancer Immunol Immunother. 2010; 59(6):943-53.
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer
McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G.
J Clin Oncol. 2009; 27:4047-4054.
Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T-cells
Johnson LE, Frye TP, Chinnasamy N, Chinnasamy G, and McNeel DG.
Cancer Immunol Immunother. 2007; 56(6):885-95.
Safety and immunological efficacy of prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP)
Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, and McNeel DGVaccine.
2006; 24:293-303.
New approaches to identification of antigenic candidates for future prostate cancer immunotherapy
Dunphy EJ, Johnson LE, Olson BM, Frye TP, McNeel DG.
Update on Cancer Therapeutics. 2006; 22:273-284.
Books
Neuropsychology of Cancer and Oncology (2012)
Chapter: Neuropsychology of Genitourinary Malignancies
Authors: Frye TP, Miller J, Tarter TH
Publisher: Springer Publishing Company 2012
Ratings & Reviews
At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.